Bin Wu, associate professor in the department of Biophysics and Biophysical Chemistry at the School of Medicine, visited ...

Degradation and failure prediction ensures the safe and reliable operation of X-ray tube. This article proposes a filament degradation prediction method for X-ray tubes based on Internet of Medical ...

Another reason for choosing a particular modality is that it is a team’s specialty. Strategic choices can be less about determining which modality best fits a potential target than about choosing a ...

Advancements in mRNA vaccine technology are reshaping medicine, addressing challenges and expanding applications from ...

A team of University of Kentucky Markey Cancer Center researchers has found the mechanism that grants prostate cancer ...

Key suits were filed by third party mRNA and lipid pioneers that, while not having any mRNA-based products on the market themselves, leveraged their patent portfolios claiming a share of the ...

Mount Sinai Center for Therapeutics Discovery, Departments of Pharmacological Sciences, Oncological Sciences and Neuroscience, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York ...

The global lipid nanoparticles market, valued at US$ 820.51 million in 2023, is projected to experience significant growth, with an expected market valuation of US$ 2,387.98 million by 2032. This ...

The surprise delay is casting new uncertainty on the fate of another vaccine awaiting FDA action: Moderna’s next-generation Covid-19 shot, called mRNA-1283, which is set for a decision by May 31.

The partnership’s main focus is on developing the nasally delivered mRNA vaccine targeting influenza. Credit: mi_viri/Shutterstock. Ethris has partnered with contract development and manufacturing ...

Ethris and Lonza agreed to collaborate on the development of room-temperature stable, spray-dried formulations of mRNA-based vaccine candidates, designed for mucosal delivery to combat respiratory ...

NEW YORK – The US Food and Drug Administration has cleared CureVac to begin a Phase I trial of its mRNA-based precision immunotherapy CVHNLC in patients with squamous non-small cell lung cancer, the ...